Bao-Hong Liu

Bao-Hong Liu

Auto-generated profile, based on publicly available information

Bao-Hong Liu

Shanghai Center for Bioinformation Technology, Shanghai 201203, China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2011 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
HYHui Yu
Hui Yu
BLBao-Hong Liu
Bao-Hong Liu
ZYZhi-Qiang Ye
Zhi-Qiang Ye
CLChun Li
Chun Li
YLYi-Xue Li
Yi-Xue Li
YLYuan-Yuan Li
Yuan-Yuan Li
Background: Differential coexpression analysis (DCEA) is increasingly used for investigating the global transcriptional mechanisms underlying phenotypic changes. Current DCEA methods mostly adopt a gene connectivity-based strategy to estimate differential coexpression, which is characterized by comparing the numbers of gene neighbors in different coexpression networks. Although it simplifies the calculation, this strategy mixes up the identities of different coexpression neighbors of a gene, and fails to differentiate significant differential coexpression changes from those trivial ones. Especially, the correlation-reversal is easily missed although it probably indicates remarkable biological significance.Results: We developed two link-based quantitative methods, DCp and DCe, to identify differentially coexpressed genes and gene pairs (links). Bearing the uniqueness of exploiting the quantitative coexpression change of each gene pair in the coexpression networks, both methods proved to be superior to currently popular methods in simulation studies. Re-mining of a publicly available type 2 diabetes (T2D) expression dataset from the perspective of differential coexpression analysis led to additional discoveries than those from differential expression analysis.Conclusions: This work pointed out the critical weakness of current popular DCEA methods, and proposed two link-based DCEA algorithms that will make contribution to the development of DCEA and help extend it to a broader spectrum.

1 January 2013 in BMC Genomics
Verified
Journal Article
Open access
PDF file
YLYuan-Yuan Li
Yuan-Yuan Li
XCXiao Chang
Xiao Chang
WYWen-Bang Yu
Wen-Bang Yu
HLHao Li
Hao Li
ZYZhi-Qiang Ye
Zhi-Qiang Ye
YLYixue Li
Yixue Li
S. erythraea is a Gram-positive filamentous bacterium used for the industrial-scale production of erythromycin A which is of high clinical importance. In this work, we sequenced the whole genome of a high-producing strain (E3) obtained by random mutagenesis and screening from the wild-type strain NRRL23338, and examined time-series expression profiles of both E3 and NRRL23338. Based on the genomic data and transcriptpmic data of these two strains, we carried out comparative analysis of high-producing strain and wild-type strain at both the genomic level and the transcriptomic level.

6 June 2014 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ZYZhi-Qiang Yin
Zhi-Qiang Yin
JLJian-Jun Liu
Jian-Jun Liu
YXYing Xu
Ying Xu
JYJian Yu
Jian Yu
GDGuo-Hui Ding
Guo-Hui Ding
HWHongxia Wang
Hongxia Wang
The aim of this study was to evaluate the ability of a 41-gene signature derived from breast cancer stem cells (BCSCs) to estimate the risk of metastasis and survival in breast cancer patients. The centroid expression of the 41-gene signature derived from BCSCs was applied as the threshold to classify patients into two separate groups—patients with high expression (high-EL) of the prognostic signature and patients with low expression (low-EL). The predictive ability of the 41-gene signature was evaluated by Cox regression model and was compared against other popular tests, such as Oncotype and MammaPrint. Our results showed that the 41-gene prognostic signature was significantly associated with age (P = .0351) and ER status (P = .0095). The analysis indicated that patients in the high-EL group had a worse prognosis than those in the low-EL group in terms of both overall survival (OS: HR, 2.05, P = .009) and distant metastasis-free survival (DMFS: HR, 2.24, P = .002). Additionally, the 41-gene signature was an independent risk factor and separates patients based on estrogen receptor status. While comparable to Oncotype, the analysis demonstrated that the 41-gene signature had a better prognostic value in predicting DMFS and OS than AOL, NPI, St. Gallen, Veridex, and MammaPrint. This study confirms the utility of the 41-gene signature and adds to the growing evidence that gene expression signatures of BCSCs have clinical potential to predict patient outcome and aid in treatment choice.